JUNOUnknown
Juno Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Juno Therapeutics, Inc. (JUNO), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are JUNO insiders buying or selling?
Juno Therapeutics, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since January 2018, Trabud has recorded 9 Form 4 filings for JUNO: 1 buys ($229.2K) and 8 sells ($25.3M).
Source: SEC EDGAR Form 4
Key Statistics (January 2018 – Feb 16, 2018)
Total Form 4 filings
9
SEC EDGAR
Insider filers
4
Insider buys (1)
$229.2K
Insider sells (8)
$25.3M
Insider sentiment
Net sellingNet insider flow of $25.1M in net selling since January 2018.
Recent JUNO insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Feb 16, 2018 | Robert Azelby | EVP & Chief Commercial Officer | Sale | 4.2K | $85.55 | $355.8K | SEC ↗ |
| Feb 15, 2018 | Robert Azelby | EVP & Chief Commercial Officer | Sale | 4.2K | $85.55 | $355.6K | SEC ↗ |
| Feb 10, 2018 | Robert Azelby | EVP & Chief Commercial Officer | Sale | 3.5K | $85.77 | $299.9K | SEC ↗ |
| Feb 3, 2018 | Robert Azelby | EVP & Chief Commercial Officer | Sale | 4.2K | $85.78 | $357.4K | SEC ↗ |
| Jan 30, 2018 | Jay T Flatley | Director | Purchase | 10.0K | $22.92 | $229.2K | SEC ↗ |
| Jan 24, 2018 | Robert Azelby | EVP & Chief Commercial Officer | Sale | 102.5K | $86.25 | $8.8M | SEC ↗ |
| Jan 20, 2018 | Robert Azelby | EVP & Chief Commercial Officer | Sale | 29.1K | $68.61 | $2.0M | SEC ↗ |
| Jan 19, 2018 | Hans Edgar Bishop | CEO & President | Sale | 270.3K | $46.17 | $12.5M | SEC ↗ |
| Jan 10, 2018 | Richard Klausner | Director | Sale | 12.7K | $48.21 | $613.4K | SEC ↗ |
Showing the 9 most recent of 9 Form 4 filings for Juno Therapeutics, Inc..
Most active JUNO insiders
- Robert Azelby6 filings
- Hans Edgar Bishop1 filing
- Jay T Flatley1 filing
- Richard Klausner1 filing
Ask anything about JUNO insider activity
Use Trabud's AI agent to query Juno Therapeutics, Inc.'s Form 4 history in plain English — "Show me JUNO CEO purchases this year" or compare it against any other ticker.
Open the AI agentJUNO insider trading FAQ
Are Juno Therapeutics, Inc. insiders buying or selling?
Juno Therapeutics, Inc. insiders reported no open-market purchases or sales in the last 12 months. Since January 2018, Trabud has recorded 9 Form 4 filings for JUNO: 1 buys ($229.2K) and 8 sells ($25.3M). Over the full record that is net selling of $25.1M.
How many insiders trade JUNO stock?
4 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Juno Therapeutics, Inc.. The most recent filing was accepted on Feb 16, 2018.
Where does Trabud get JUNO insider trading data?
All JUNO insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.